Relationship among Left Ventricular Hypertrophy, Cardiovascular Events, and Preferred Blood Pressure Measurement Timing in Hemodialysis Patients
Open Access
- 29 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3512
- https://doi.org/10.3390/jcm9113512
Abstract
This study aimed to identify the ideal timing and setting for measuring blood pressure (BP) and determine whether the left ventricular mass index (LVMI) is an independent risk factor associated with increased cardiovascular events in hemodialysis (HD) patients. BP and LVMI were measured at baseline and at 6 and 12 months after HD initiation. BP was monitored and recorded at nine different time points, including before and after HD over a one-week period (HDBP). The mean BP measurement was calculated as the weekly averaged BP (WABP). LVMI was significantly correlated with home BP, in-office BP, HDBP, and WABP. Receiver operating characteristic analysis indicated that the cutoff LVMI value for cardiovascular events was 156 g/m2. LVMI and diabetes mellitus were significant influencing factors for cardiovascular events (hazards ratio (95% confidence interval): diabetes mellitus, 2.84 (1.17,7.45); LVMI > 156 g/m2, 2.86 (1.22,6.99)). Pre-HDBP, post-HDBP, and WABP were independently associated with higher LVMI in the follow-up periods. Hemoglobin and human atrial natriuretic peptide (hANP) levels were associated with LVMI beyond 12 months after HD initiation. Treatment of hypertension, overhydration based on hANP, and anemia may reduce the progression of LVMI and help identify HD patients at high risk for cardiovascular events.This publication has 25 references indexed in Scilit:
- Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo studyHypertension Research, 2011
- Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart StudyJournal of Hypertension, 2011
- Predictive Factors Associated with Left Ventricular Hypertrophy at Baseline and in the Follow‐Up Period in Non‐Diabetic Hemodialysis PatientsSeminars in Dialysis, 2010
- Left Ventricular Hypertrophy in New Hemodialysis Patients without Symptomatic Cardiac DiseaseClinical Journal of the American Society of Nephrology, 2010
- Left Ventricular Mass in Chronic Kidney Disease and ESRDClinical Journal of the American Society of Nephrology, 2009
- Weekly Averaged Blood Pressure Is More Important than a Single-Point Blood Pressure Measurement in the Risk Stratification of Dialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Review: New approaches to the assessment of left ventricular hypertrophyTherapeutic Advances in Cardiovascular Disease, 2007
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Hypoalbuminemia as a Risk Factor for Progressive Left-Ventricular Hypertrophy in Hemodialysis PatientsAmerican Journal of Nephrology, 2000
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986